|
Market Report
|
HIV - Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.
|
|
Read more...
|
|
|
Market Report
|
 Upper GI Disorders - Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
|
|
Read more...
|
|
|
Market Report
|
The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
|
|
Read more...
|
|
|
Market Report
|
New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
|
Market Report
|
Empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image.
|
|
Read more...
|
|
|
Market Report
|
Pediatric and Adolescent Vaccines
The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.
|
|
Read more...
|
|
|
Market Report
|
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
|
|
Read more...
|
|
|
Market Report
|
Health Care Equipment and Supplies: Global Industry Guide
Datamonitor's Health Care Equipment & Supplies: Global Industry Guideis an essential resource for top-level data and analysis covering the health care equipment & supplies industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
|
|
Read more...
|
|
|
Company Report
|
Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity.
|
|
Read more...
|
|
|
Market Report
|
Heart failure - Weak pipeline dominated by new indications and add-on diuretics
Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
|
|
Read more...
|
|
|
Market Report
|
Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
|
|
Read more...
|
|
|
Market Report
|
Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products
The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.
|
|
Read more...
|
|
|
Company Report
|
Business Blogging for Pharma
Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.
|
|
Read more...
|
|
|
Market Report
|
Hospital Antibacterials A market beyond MRSA
The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.
|
|
Read more...
|
|
|
Product Report
|
Regulatory and development issues hurdles exist but are surmountable
Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls.
|
|
Read more...
|
|
|
Market Report
|
Online Pharmacies - Implications for the Pharmaceutical Industry
Online pharmacies are playing an increasing role in the prescription pharmaceutical industry as patients seek the convenience and in some cases cost benefits that they can provide. However while online pharmacies offer considerable benefits there are also risks attached to their increasing role.
|
|
Read more...
|
|
|
Product Report
|
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.
|
|
Read more...
|
|
|
Market Report
|
Migraine - Opportunities will exist in the wake of generic attack
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
|
|
Read more...
|
|
Farmavita.Net Journal 
